MeiraGTx Holdings plc develops clinical-stage genetic medicines for diseases with high unmet need, with recurring updates centered on AAV gene therapy programs, ocular disease, radiation-induced xerostomia, and regulated gene-expression technology. Company news includes clinical disclosures for AAV-hAQP1 and AAV2-hAQP1 in grade 2/3 radiation-induced xerostomia, ophthalmology programs such as AAV-AIPL1 for Leber congenital amaurosis 4, and the acquired bota-vec program for X-linked retinitis pigmentosa.
Updates also cover strategic collaborations and license agreements, in-house manufacturing capabilities for genetic medicines, riboswitch platform development, operating results, financing arrangements, shareholder voting matters, and capital-structure disclosures tied to MGTX ordinary shares.
MeiraGTx Holdings plc (MGTX) announced its Q2 2020 results, highlighting positive initial data from the Phase 1/2 trial of AAV-RPGR for X-linked retinitis pigmentosa, leading to its advancement into the Phase 3 Lumeos trial. The company also unveiled plans for new manufacturing facilities in Shannon, Ireland, set to enhance production capabilities. Financially, MeiraGTx reported a net loss of $25.4 million and cash reserves of $194.8 million. License revenue increased to $2.5 million, while R&D expenses rose to $16.2 million, influenced by costs from clinical trials and a recent acquisition.
MeiraGTx Holdings (MGTX) announced positive results from the Phase 1/2 clinical trial of AAV-RPGR, aimed at treating X-linked retinitis pigmentosa (XLRP). Significant improvements in vision were observed in patients after six months, with favorable safety and efficacy profiles noted. As a result, MeiraGTx and Janssen plan to progress AAV-RPGR into the Phase 3 Lumeos trial. The findings were presented at the ASRS 2020 Virtual Annual Meeting, highlighting the potential of AAV-RPGR as a significant advancement in treating a disease currently lacking approved therapies.
MeiraGTx Holdings plc (MGTX) reported Q1 2020 financial results, highlighting a net loss of $15.7 million, or $0.43 per share, an improvement from $18 million, or $0.62 per share, in Q1 2019. The company had cash, cash equivalents, and restricted cash totaling approximately $211 million, sufficient to fund operations into 2022. License revenue rose to $4.2 million, driven by a collaboration agreement with Janssen. R&D expenses decreased to $8.1 million, while G&A expenses increased to $11.8 million. MeiraGTx remains focused on its clinical programs despite COVID-19 challenges.
MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical stage gene therapy company, will have its CEO, Alexandria Forbes, present at the Virtual Bank of America Securities 2020 Health Care Conference on May 12, 2020, at 10:20 a.m. ET. Interested parties can access the live webcast on the Company's Investors page, with a replay available for 30 days. MeiraGTx specializes in gene therapies targeting inherited retinal diseases, neurodegenerative diseases, and xerostomia, supported by a strong pipeline and advanced manufacturing capabilities.